Is Altria (MO) Quietly Rewriting Its Investment Story Around Smoke-Free Growth and Buybacks?

• In late July 2026, Altria Group reported second-quarter 2026 results showing sales of US$5,356 million, slightly higher than a year earlier, while net income and earnings per share from continuing operations dipped modestly and the company continued its share repurchase program.
• Management also modestly raised full-year adjusted earnings guidance on the back of cigarette pricing and growth in smoke-free products, particularly nicotine pouches, while signaling ongoing investment and regulatory progress in its reduced-risk portfolio.
• We’ll now examine how the improved full-year guidance, underpinned by cigarette pricing and smoke-free investments, affects Altria’s investment narrative.

AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Altria Group Investment Narrative Recap

To own Altria today, you generally have to believe its core cigarette franchise can keep funding a shift toward smoke free products while supporting ongoing cash returns. The latest results, with slightly higher sales but softer quarterly earnings, do not materially change that picture. The key near term catalyst remains execution in nicotine pouches and other reduced risk products, while regulatory and legal uncertainty around nicotine and e vapor still looks like the biggest risk.

The most relevant announcement alongside Q2 earnings is Altria’s ongoing share repurchase program, which has retired about 1.33% of shares since early 2025. While modest in size, this sits alongside a long running dividend and matters for investors who care about per share earnings and capital returns, especially as management modestly lifts adjusted EPS guidance on the back of cigarette pricing and smoke free growth.

Yet against this steady picture, the regulatory and litigation overhang around e vapor and reduced risk products is something investors should be aware of, because it...

Read the full narrative on Altria Group (it's free!)

Altria Group’s narrative projects $20.9 billion revenue and $9.7 billion earnings by 2029. This implies fairly flat yearly revenue growth and an earnings increase of about $1.7 billion from $8.0 billion today.

Uncover how Altria Group's forecasts yield a $70.36 fair value, a 3% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were already more cautious, assuming roughly flat revenue near US$20.7 billion and earnings of about US$9.5 billion by 2029, and their concerns about smoke free headwinds such as illicit e vapor competition could look very different in light of Altria’s updated guidance.

Explore 4 other fair value estimates on Altria Group - why the stock might be worth over 2x more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Altria Group research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Altria Group research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Altria Group's overall financial health at a glance.

Contemplating Other Strategies?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Outshine the giants: these 16 early-stage AI stocks could fund your retirement.
• Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Find 55 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com